Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 980.45M | 716.91M | 533.88M | 354.56M | 253.54M |
Gross Profit | 761.52M | 506.03M | 391.75M | 247.44M | 166.99M |
EBITDA | 303.80M | -97.87M | -413.31M | -378.12M | -318.44M |
Net Income | 33.54M | -382.95M | -602.16M | -585.60M | -542.97M |
Balance Sheet | |||||
Total Assets | 2.42B | 2.45B | 2.80B | 2.30B | 2.33B |
Cash, Cash Equivalents and Short-Term Investments | 381.18M | 434.04M | 611.27M | 566.45M | 950.04M |
Total Debt | 570.28M | 544.11M | 415.28M | 538.35M | 463.80M |
Total Liabilities | 1.58B | 1.66B | 1.65B | 1.05B | 868.28M |
Stockholders Equity | 834.06M | 785.89M | 1.15B | 1.25B | 1.45B |
Cash Flow | |||||
Free Cash Flow | 174.12M | -203.26M | -543.94M | -564.45M | -531.73M |
Operating Cash Flow | 211.25M | -76.65M | -303.27M | -365.78M | -225.31M |
Investing Cash Flow | -137.12M | -100.28M | -153.74M | -84.13M | -188.18M |
Financing Cash Flow | -92.03M | -37.82M | 587.20M | 219.44M | 868.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | HK$8.47B | 235.64 | 4.16% | ― | 34.39% | ― | |
57 Neutral | HK$8.86B | ― | -13.97% | ― | -97.81% | -117.20% | |
57 Neutral | HK$9.22B | ― | -51.40% | ― | 58.75% | -1310.16% | |
57 Neutral | £4.81B | 6.73 | -62.36% | 5.45% | 34.03% | 6.31% | |
53 Neutral | HK$12.90B | ― | -55.68% | ― | ― | -4.33% | |
51 Neutral | HK$14.04B | ― | -18.87% | ― | 16.35% | -49.63% | |
― | HK$9.82B | 111.20 | 4.95% | ― | ― | ― |
Biocytogen Pharmaceuticals announced a voluntary share repurchase plan, approved at its 2024 AGM, to buy back up to 11,078,192 H Shares, representing 10% of its H Shares and 2.77% of its total issued share capital, using internal funds up to HK$50 million over the next 24 months. The repurchased shares may be held as Treasury Shares or used for employee share awards, with the company appointing Kastle Limited to manage the repurchase and CMB Wing Lung (Trustee) Limited to oversee the Share Award Scheme, all while adhering to regulatory requirements and market conditions.
Biocytogen Pharmaceuticals has secured a patent in Japan for its RenMab™ fully human antibody mouse platform, marking a significant milestone in its global intellectual property strategy. This achievement enhances the company’s competitive edge in the biotech industry, as the RenMice platform has already generated numerous licensing agreements and high-potential therapeutic candidates, underscoring its substantial commercial value and global recognition.
Biocytogen Pharmaceuticals held its 2024 Annual General Meeting on May 28, 2025, combining a physical and virtual format. The meeting saw participation from shareholders representing 81.27% of the total voting shares. Key resolutions were voted on, with certain shareholders abstaining due to conflicts of interest, ensuring compliance with regulatory requirements. All resolutions were passed by poll, reflecting strong shareholder support and adherence to corporate governance standards.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for May 28, 2025, which will be held both physically and virtually. The meeting will address key resolutions including the approval of the 2024 annual report, financial statements, and remuneration plans for directors and supervisors. Additionally, a special resolution will be considered regarding the repurchase of H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.